



Efficacy and Safety of Riluzole in Acute Spinal Cord Injury (SCI). Rationale and Design of AOSpine Phase

III Multi-center Double Blinded Randomized Controlled Trial. (RISCIS)

Michael G. Fehlings MD, PhD, FRCS(C), FACS; Branko Kopjar MD; Robert G. Grossman MD  
University of Toronto, Toronto, ON, Canada; University of Washington, Seattle, WA, USA;  
The Methodist Hospital, Houston, TX, USA



Background

Over 1 million people living with Spinal Cord Injury (SCI) in North America alone. Annual costs for the acute treatment and chronic care of these patients totaling four billion dollars USD. Beyond supportive care, there are no medical or surgical treatments that have been clearly demonstrated to improve functional outcome in human SCI.

Phase I/IIa Riluzole Trial

The primary aim: To develop acute care safety and pharmacokinetic profiles of riluzole in patients who have sustained a traumatic spinal cord injury. Secondary objectives: To conduct exploratory analyses of neurological outcomes for purposes of planning a subsequent Phase II b – Phase III randomized study of the efficiency of riluzole for the treatment of acute spinal cord injury

Patient Characteristics	
Characteristic	Patient Number N=36
Gender:	
Male	30 (83%)
Female	6 (17%)
Mean Age	39 (Min:18 Max:69)
Neurological Level of Injury:	
Cervical	28 (78%)
Thoracic	8 (22%)
ASIA Impairment Scale (AIS) grade:	
AIS grade A	19 (53%)
AIS grade B	9 (25%)
AIS grade C	8 (22%)
Etiology:	
Motor Vehicle Accident	20(55%)
Fall	9(25%)
Sport related	5(14%)
Assault	2 (6%)

Phase I/IIa Trial Results

	Riluzole N = 36		Registry N = 36		
System/Category	Patients <sup>1</sup>	Incidence <sup>2</sup>	Patients <sup>1</sup>	Incidence <sup>2</sup>	P-value <sup>3</sup>
Infection	14	0.389	13	0.361	0.81
Pulmonary	11	0.306	16	0.444	0.22
Neuropsychiatric	10	0.278	10	0.278	1.00
Hematological	7	0.194	9	0.250	0.57
Cardiovascular	5	0.139	11	0.306	0.09
GI/GU	5	0.139	9	0.250	0.19
Skin	4	0.111	3	0.083	0.69

Phase I/IIa Trial: Conclusion

Have established feasibility of a multicenter trial evaluating Riluzole in traumatic SCI  
Preliminary safety and neurological recovery data appear promising

Phase III RCT

Subjects

A total of 351 patients with acute traumatic SCI will be randomized in a prospective double-blind placebo-controlled trial involving up to 35 sites internationally.

Randomization will be 1:1 to riluzole 2x100mg daily for 24 hours followed by 2x50mg daily for the following 13 days after injury, or to the same regimen of placebo.

Key inclusion criteria include: able to receive study drug within 12 hours of injury; ISNCSCI Impairment Scale Grade A, B or C; level of injury C4-C8  
Key exclusion criteria include: injury from penetrating mechanism, significant concomitant head injury

Study Design

Primary outcome measure is change in ISNCSCI Total Motor Score between baseline and 180 days following enrollment. Secondary outcomes measures include ISNCSCI grade, ISNCSCI Sensory Scores, SCIM, SF-36v2, EQ-5D, GRASSP, Pain NRS

Statistical Design

Sample size of 316 evaluable subjects will have 90% power to detect .37 Cohen’s d effect size (i.e. 9 difference in ISNCSCIMS). There is no published minimally significant difference for ISNCSCIMS. The current effect estimate of 9 is arbitrarily set. Study uses adaptive sequential design that allows sample size change during the interim analysis. In order to account for loss of power due to loss of follow-up and possible adjustments for baseline factors we will increase sample size by 10% to 351 enrolled subjects.

Plan ID	Parameter
Type of the hypothesis	1-Sided
Type I Error (α)	0.025
Power (1 - β)	0.90
Randomization Ratio (Investigational vs. Control)	1:1
Planned Number of Interim Looks	2
Spacing of Looks	60%, 100%
Hypothesis to be Rejected	H0 or H1 (binding)
Boundary Family	Published Function
Boundary to Reject H0	O'Brien-Fleming
Boundary to Reject H1	Gamma (-1)
Difference of Means Assuming H1	9
Standard Deviation (σ)	24.08
Sample Size	316 (158 per arm)

Current Status

Subject enrollment for this trial began on October 1, 2013 in 11 international centers. This is a Phase III study of riluzole in acute SCI. To date, there are 25 subjects enrolled.

Results

ASIA at arrival and Pre-injury Status		
Outcome Measure		Mean (Standard Deviation)
ASIA	ASIA Grade (N =20)	A : 11 (46%) B: 7 (29%) C: 6 (25%)
	Motor Total (N =24)	15.4 (12.9)
	Sensory Light Touch (N =21)	39.6 (25.6)
	Sensory Pin Prick (N =21)	39.8 (23.7)
	Upper Extremity Motor Score (N =24)	14.4 (11.1)
	Lower Extremity Motor Score (N =24)	4.0 (7.8)
Pain (N=18)		3.7 (3.3)
GRASSP (N =11)		53.0 (70.7)
SF36v2 PCS (pre-injury recall) (N=19)		52.2 (8.3)
SF36v2 MCS (pre-injury recall) (N=19)		55.2 (13.8)
EQ-5D (pre-injury recall) (N =20)		0.9 (0.2)
Demographics		
Demographics		N (%)
Age (N = 25)	46.9±16.7	
Gender	Female	3 (12%)
	Male	22 (88%)
Race	White	19 (76%)
	African-American	3 (12%)
	Asian	2 (8%)
	Alaska Native	1 (4%)

Conclusions

This is a Phase III study of riluzole in acute SCI.

Acknowledgements

This study is funded by AOSpine North America Inc., a 501(c) 3 non-profit corporation

